Suggested Readings

Phenotypic characterization of eosinophilic esophagitis in a large multicenter patient population from the Consortium for Food Allergy Research.

Chehade M, et al. J Allergy Clin Immunol Pract. 2018;6(5):1534-1544.e5.

Differences between childhood- and adulthood-onset eosinophilic esophagitis: an analysis from the EoE connect registry.

Laserna-Mendieta EJ, et al. Dig Liver Dis. 2023;55(3):350-359.

A practical update on pediatric eosinophilic esophagitis.

Votto M, et al. Children (Basel). 2023;10(10):1620.

Mechanisms of disease of eosinophilic esophagitis.

Davis BP, Rothenberg ME. Annu Rev Pathol. 2016;11:365-393.

Dupilumab in adults and adolescents with eosinophilic esophagitis.

Dellon ES, et al. N Engl J Med. 2022;387(25):2317-2330.

Dupilumab for eosinophilic esophagitis in patients 1 to 11 years of age.

Chehade M, et al. N Engl J Med. 2024;390(24):2239-2251.

Diagnosis and treatment of eosinophilic esophagitis.

Gonsalves NP, Aceves SS. J Allergy Clin Immunol. 2020;145(1):1-7.

Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial.

Hirano I, et al. Clin Gastroenterol Hepatol. 2022;20(3);525-534.

Functional lumen imaging probe for the management of esophageal disorders: expert review from the clinical practice updates committee of the AGA Institute.

Hirano I, et al. Clin Gastroenterol Hepatol. 2017;15(3):P325-P334.

Type 2 inflammation in eosinophilic esophagitis: from pathophysiology to therapeutic targets.

Racca F, et al. Front Physiol. 2021;12:815842.

Related activities
Webcast Series 
0.25 AMA PRA

Eosinophilic Esophagitis Pathophysiology and Burdens

Module 1

Faculty: Evan Dellon, MD, MPH; Carla M. Davis, MD
Release: 12/16/2024
Expiration: 12/16/2025
Webcast Series 
0.25 AMA PRA

Diagnosing Eosinophilic Esophagitis

Module 2

Faculty: Evan Dellon, MD, MPH; Carla M. Davis, MD
Release: 12/20/2024
Expiration: 12/20/2025